I have abbott labs which is also down.
There could be a funny situation if there is indeed a "cure" for obesity.. will people just eat Mcdonalds everyday and stuff their faces.
Printable View
Who knows, maybe FPH moves at some stage even into the "fair value" region - which, according to my crystal ball would be around $15. Though - according to Grahams formula the share is less than $9 but shareclarity (DCF) puts them on $19.15;
What have all these numbers in common? Well, of course, they are all below $20 - and they all have been calculated before the hype around this new weight-loss medication emerged.
Maybe it is a fair value drug?
Hyperion buying more.....now up over 6%
http://nzx-prod-s7fsd7f98s.s3-websit...901/405054.pdf
FPH shud not be that much affected as RMD by this new anti obesity drug ....they derive 2/3 of their revenues from hospital equipment and consumables and small part from OSA related ....dont know how anti obesity drug will change their hospital humidification business ?? Maybe baby ie FPH getting dumped unjustly ...or there is an opportunity in FPH developing ????
Not a good look this headline in BusinessDesk
Bullying claims emerge at F&P Healthcare
Suppose bullying happens somewhere in big most work places, nobody is perfect
Like bullying happens on Sharetrader Forum also ....lol :p
Mainfreight share price up 16% since reporting things getting back to normal
FPH report next week ..hope they say things are normalising and share price goes up 16% …or $26.50
That’ll be good
https://www.nzx.com/announcements/422577
Fisher & Paykel Healthcare announces results for the first half of the 2024 financial year
Auckland, New Zealand, 29 November 2023 - Fisher & Paykel Healthcare Corporation Limited (NZX:FPH, ASX:FPH) today announced its results for the first half of the 2024 financial year.
For the six months ended 30 September 2023, total operating revenue was $803.7 million, a 16% increase from the prior corresponding period in both reported and constant currency. Net profit after tax for the first half was $107.3 million, a 12% increase from the same period in the previous financial year, or a 22% increase in constant currency.
“Our first half result indicates a continuation of stable ordering patterns in our Hospital business and a robust performance for Homecare,” said Managing Director and Chief Executive Officer Lewis Gradon.
In the Hospital product group, which includes humidification products used in respiratory, acute and surgical care, revenue for the first half was $487.5 million. This marks an increase of 11% on the prior comparable period, and 11% in constant currency. Hospital new applications consumables grew 19% in constant currency.
"Apparent growth rates this financial year will be impacted by COVID-19 effects throughout last year," said Mr Gradon. "We continued to see strong demand for hospital consumables across the product portfolio in the first half, and hardware demand was solid. We remain pleased with the progress we are making on changing clinical practice."
In the Homecare product group, which includes products used in the treatment of obstructive sleep apnea (OSA) and respiratory support in the home, revenue was $314.4 million, a 26% increase over the prior comparable period, or 25% in constant currency. OSA masks and accessories revenue increased 28% in constant currency.
“Evora Full has been available in the United States for more than a year, and it continues to see impressive demand and positive customer feedback,” said Mr Gradon. “We are set to build on this momentum next year as our revolutionary new F&P Solo mask is rolled out beyond New Zealand and Australia.”
Gross margin was 60.5%, up 65 basis points, or 192 basis points in constant currency, compared to the first half of the 2023 financial year.
“Headwinds such as freight rates and manufacturing inefficiencies continue to ease, while inflationary raw material and manufacturing costs remain key areas of focus for our teams,” said Mr Gradon. “We remain confident in our ability to return to our long-term target of 65% within three to four years.”
The company’s directors have approved an interim dividend of 18.0 cents per ordinary share, up from 17.5 cents per share in the prior corresponding period. The interim dividend, carrying full New Zealand imputation credit, will be paid on 18 December 2023 with a record date of 6 December 2023. The company’s dividend reinvestment plan remains available to eligible shareholders with a 3% discount applying to this interim dividend.
Looking ahead
“At current exchange rates*, we expect operating revenue for the 2024 financial year to be approximately $1.7 billion and net profit after tax to be in the range of approximately $250 million to $260 million.
“Historically, sales of our hospital consumables are typically higher in the second half, reflecting seasonal patterns of hospitals,” said Mr Gradon. “We are currently expecting that our revenue
guidance approximation incorporates the range of pre-COVID historical seasonality in hospital consumables.”
*At 31 October 2023 exchange rates of NZD:USD 0.58, NZD:EUR 0.55, NZD:MXN 10.55.
Overview of key results for the first half of the 2024 financial year
• 12% increase in net profit after tax to $107.3 million, 22% increase in constant currency.
• 16% increase in operating revenue to $803.7 million, 16% increase in constant currency.
• 11% increase in Hospital operating revenue to $487.5 million, 11% increase in constant currency.
• 19% increase in constant currency for new applications consumables (products used in noninvasive ventilation, Optiflow nasal high flow and surgical applications) accounting for 70% of Hospital consumables revenue.
• 26% increase in Homecare operating revenue to $314.4 million, 25% increase in constant currency.
• 28% increase in constant currency for OSA masks and accessories revenue.
• Investment in R&D was 12% of revenue, or $96.9 million.
• 3% increase in interim dividend to 18.0 cps (H1 FY23: 17.5 cps).
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.
Ends
good result. chart looks good too
it beats the street.